| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/25/2004 | WO2002051433A3 Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament |
| 03/25/2004 | WO2002044342A3 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| 03/25/2004 | WO2002034288A8 Vaccine for treating allergy |
| 03/25/2004 | WO2002017899A3 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/25/2004 | US20040060077 Using dietary restriction to lower serum insulin levels and function as tool in treatment and prevention of alzheimer's diseases |
| 03/25/2004 | US20040059383 Methods of indirectly stimulating the vagus nerve with an electrical field |
| 03/25/2004 | US20040059281 Delivery system and method of treating or preventing otitis media |
| 03/25/2004 | US20040059241 Method for classifying and treating physiologic brain imbalances using quantitative EGG |
| 03/25/2004 | US20040059132 Reacting an indolin-2-one derivative with substituted benzyl halide to form substituted N-benzyl indolin-2-one derivatives have an affinity for oxytocin receptors |
| 03/25/2004 | US20040059115 Such as ((benzylsulfonylamino)methyl)-phosphonic acid mono-(4-nitrophenyl)ester sodium salt; for treating bacterial antibiotic resistance |
| 03/25/2004 | US20040059017 Method for producing a partial or complete active ingredient coating on and in implants and onplants |
| 03/25/2004 | US20040058999 Aids therapy; using xanaldial, xenalamine, xenalic acid |
| 03/25/2004 | US20040058994 Local prevention or amelioration of pain from surgically closed wounds |
| 03/25/2004 | US20040058987 Hypotensive agents; oxidation resistance, nitrogen scavenger; anticancer agents; antiischemic agents |
| 03/25/2004 | US20040058986 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 03/25/2004 | US20040058984 Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans |
| 03/25/2004 | US20040058975 Using prostaglandin antagonist and cyclooxygenase inhibitor; contraceptive; delay releasing oocytes |
| 03/25/2004 | US20040058940 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 03/25/2004 | US20040058939 Derivatives of variolin b |
| 03/25/2004 | US20040058925 Method of treating fibromyalgia and other somatoform disorders |
| 03/25/2004 | US20040058914 Combination drugs |
| 03/25/2004 | US20040058908 Mixture of bile acid transport inhibitor, cholesteryl ester transport protein inhibitor, fibric acid, nicotinic acid, microsomal triglyceride transfer protein inhibitor and sterols |
| 03/25/2004 | US20040058897 Estrogenic substances combined with cruciferous indole compounds |
| 03/25/2004 | US20040058896 Uniform dispersion in excipient of fatty acid, triglyceride and,or fatty ester |
| 03/25/2004 | US20040058893 Sexual disorders, aids, hepatitis virus |
| 03/25/2004 | US20040058884 Detecting diseases by Selex method; anticancer agents |
| 03/25/2004 | US20040058883 Oligonucleotide compositions and their use for the modulation of immune responses |
| 03/25/2004 | US20040058869 Methods and reagents for modulating cholesterol levels |
| 03/25/2004 | US20040058868 Using insulin receptor substrate and histone deacetylase inhibitor; regenerating insulin sensitivity |
| 03/25/2004 | US20040058857 Mixture of glucocorticoids and prostate specific antigen, or complex thereof; anticancer agents |
| 03/25/2004 | US20040058853 Multivalent neuraminidase inhibitor conjugates |
| 03/25/2004 | US20040058443 Manipulation of non-terminally differentiated cells using the Notch pathway |
| 03/25/2004 | US20040058399 Evaluating effectiveness of isoniazid preventive therapy in treating tuberculosis |
| 03/25/2004 | US20040058366 Comprises DNA coding brain-muscle-arnt-like protein 2 (BMAL2) for diagnosis and treatment of circadian rythm disorders |
| 03/25/2004 | US20040058353 Comprises nucleotide sequences coding transport proteins for diagnosis and treatment of pain, psychotic, eating and nervous system disorders |
| 03/25/2004 | US20040058342 Comprises serine protease for diagnosis, prognosis and treatment of cell proliferative disorders |
| 03/25/2004 | US20040058326 Identification and use of molecules implicated in pain |
| 03/25/2004 | US20040058024 Comprises polyunsaturated fatty acid-containing composition extracted from Echium plants, with antilipemic agents, antioxidants, and antidiabetic agents, for formulation as dietary supplement |
| 03/25/2004 | US20040058021 Which suppresses I-kappa-B-alpha phosphorylation through inhibition kinase activity and downregulating NF-kappa-B; antiproliferative agents |
| 03/25/2004 | US20040058018 Novel substituted benzimidazole dosage forms and method of using same |
| 03/25/2004 | US20040058015 Nutraceuticals; for combination with herbs |
| 03/25/2004 | US20040058012 Method of dietary supplementation |
| 03/25/2004 | US20040058011 Comprises chlorhexidine acetate, zinc stearate, and carrier; nontoxic; for domesticated dairy cattle |
| 03/25/2004 | US20040058009 Nanoparticulate fibrate formulations |
| 03/25/2004 | US20040057990 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 03/25/2004 | US20040057989 Method of cancer treatment |
| 03/25/2004 | US20040057981 Gelled delivery vehicle containing nutritional ingredients |
| 03/25/2004 | US20040057954 Tumor necrosis factor antagonists and their use in endometriosis |
| 03/25/2004 | US20040057947 For therapy of ischaemic conditions |
| 03/25/2004 | US20040057944 For therapy and/or prophylaxis of maldigestion, especially maldigestion caused by pancreatic insufficiency, in humans or other mammals |
| 03/25/2004 | US20040057943 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 03/25/2004 | US20040057934 Therapeutic agent for treating retroviral infection |
| 03/25/2004 | US20040057929 Administering viruses selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus to mammal having Ras-activated pathway to result in lysis of proliferating cells |
| 03/25/2004 | US20040057917 Strengthens the pigment formation in the skin |
| 03/25/2004 | US20040055609 Treatment of hepatitis C using hyperthermia |
| 03/25/2004 | CA2532912A1 Full range nutritional supplements from plant materials and methods for their manufacture |
| 03/25/2004 | CA2498777A1 Non-sequence complementary antiviral oligonucleotides |
| 03/25/2004 | CA2498723A1 Design of chemokine analogs for the treatment of human diseases |
| 03/25/2004 | CA2498493A1 Phenyl-indole compounds |
| 03/25/2004 | CA2498378A1 Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis |
| 03/25/2004 | CA2498367A1 Viral deconstruction through capsid assembly in vitro |
| 03/25/2004 | CA2498274A1 Compositions and methods for the diagnosis of immune related diseases using pro7 |
| 03/25/2004 | CA2498225A1 Factors that bind intestinal toxins |
| 03/25/2004 | CA2498175A1 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine |
| 03/25/2004 | CA2498004A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/25/2004 | CA2498000A1 Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers |
| 03/25/2004 | CA2497801A1 Paks as modifiers of the chk pathway and methods of use |
| 03/25/2004 | CA2497793A1 Flj20647s as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | CA2497790A1 Rors as modifiers of the p21 pathway and methods of use |
| 03/25/2004 | CA2497661A1 Compositions and methods for the diagnosis of immune related diseases using pro71061 |
| 03/25/2004 | CA2497337A1 Novel composition and methods for the treatment of psoriasis |
| 03/25/2004 | CA2497182A1 Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
| 03/25/2004 | CA2497132A1 Method of diagnosing ovarian endometriosis |
| 03/24/2004 | EP1400810A2 Estrogen receptors and bone disease |
| 03/24/2004 | EP1400245A1 Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| 03/24/2004 | EP1400242A1 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor |
| 03/24/2004 | EP1400241A1 Fused cyclic compounds and medicinal use thereof |
| 03/24/2004 | EP1399744A2 Epf receptor assays, compounds and therapeutic compositions |
| 03/24/2004 | EP1399739A2 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 03/24/2004 | EP1399738A2 Glaucoma treatments with reduced hyperpigmentation |
| 03/24/2004 | EP1399593A2 Genes expressed in breast cancer as prognostic and therapeutic targets |
| 03/24/2004 | EP1399579A1 Fkbp51/52 and cyp40-mediated mammalian hair growth |
| 03/24/2004 | EP1399558A2 Vanilloid receptor-related nucleic acids and polypeptides |
| 03/24/2004 | EP1399554A2 Immunoglobulin superfamily proteins |
| 03/24/2004 | EP1399553A2 Polynucleotides encoding cellular transporters and methods of use therof |
| 03/24/2004 | EP1399542A2 Methods for modulating gap junctions |
| 03/24/2004 | EP1399501A1 Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug |
| 03/24/2004 | EP1399483A2 Antibodies to insulin-like growth factor i receptor |
| 03/24/2004 | EP1399479A2 Cation conducting gaba a receptors and their use |
| 03/24/2004 | EP1399466A2 Compounds and methods for the modulation of cd154 |
| 03/24/2004 | EP1399462A1 Combined approach to treatment of cancer using a c-myc antisense oligomer |
| 03/24/2004 | EP1399426A2 Compounds, compositions and methods for modulating beta-amyloid production |
| 03/24/2004 | EP1399423A2 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds |
| 03/24/2004 | EP1399221A1 Compositions comprising oestrone-3-o-sulphamate and trail (tnf-related apoptosis inducing ligand) |
| 03/24/2004 | EP1399215A2 Tissue-specific endothelial membrane proteins |
| 03/24/2004 | EP1399206A2 Hydrophobic dopamine agonists administered to the dermis |
| 03/24/2004 | EP1399205A2 Enhanced systemic absorption of intradermally delivered substances |
| 03/24/2004 | EP1399184A2 Uses of mammalian genes and related reagents |
| 03/24/2004 | EP1399179A2 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 03/24/2004 | EP1399175A2 Therapeutic use of rank antagonists |